Klavocin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Klavocin

Quick Facts Description
Active ingredients Amoxicillin and Clavulanic acid
Form Tablets, Oral Suspension, and Injection
Pharmacological class Penicillin (beta-Lactamase Inhibitor combination)
General purpose Overcoming bacterial resistance to clear infections
Origin Synthetic (Semi-synthetic penicillin derivative)

Klavocin is a synthetic, fixed-dose combination (FDC) antibiotic used to treat a wide range of bacterial infections. Known generically by its International Non-proprietary Name (INN), Co-amoxiclav, it is broadly classified as a broad-spectrum antibacterial agent belonging to the penicillin class of medicines. This preparation is a prescription-only medicine, available as standard tablets, an oral suspension for liquid dosing, and a powder for solution for injection, supporting both oral and parenteral administration routes. Other popular, equivalent generic and branded names containing this formulation include Augmentin and Amoclan.


The Unique Composition: Amoxicillin and Clavulanic Acid

Klavocin contains two active ingredients: Amoxicillin and Clavulanic acid (often as Clavulanate potassium). Amoxicillin is the primary agent, responsible for the drug's direct bactericidal activity. Clavulanic acid serves a protective role; it is an inhibitor that neutralizes specific enzymes produced by resistant bacteria. This unique pairing creates a necessary synergistic effect, meaning the combined effect is greater than the effect of each substance alone. Pharmacological studies confirm this combination is an essential component of modern therapeutic regimens due to its ability to retain activity against beta-lactamase producing organisms.


General Purpose of the Dual-Component Strategy

The general purpose of combining Amoxicillin with Clavulanic acid is to restore and expand the power of the Amoxicillin component. This strategic design overcomes a key defense mechanism—the beta-lactamase enzyme—that some resistant bacteria use to inactivate the antibiotic. The drug’s core function is reliably ensuring the clearance of susceptible bacterial pathogens, making it a common choice for infections where bacterial resistance is suspected. This confirms that the second component acts purely to protect the primary antibiotic, not to kill bacteria directly.

Regulatory References

  1. Amoxicillin + clavulanic acid on the WHO Model List of Essential Medicines
  2. Clavulanic Acid - NCBI StatPearls

What side effects are possible with Klavocin?

Klavocin (amoxicillin/clavulanate) is generally well-tolerated, but like all medications, it can cause side effects. Understanding potential reactions is important for patient safety.

Common Side Effects

The most frequently reported side effects, typically affecting up to 1 in 10 people, are often mild and include:

  • Gastrointestinal issues: Diarrhea, loose stools, nausea, and vomiting. Taking the medication with food may help minimize gastrointestinal upset.
  • Fungal Infections: Vaginal yeast infections (vaginitis) and oral thrush (yeast infection in the mouth).
  • Skin reactions: Skin rash and itching.

Serious and Less Common Side Effects

Certain side effects, while less common, can be serious and require immediate medical attention:

  • Allergic Reactions: Signs of a severe allergic reaction (anaphylaxis) include swelling of the face, lips, tongue, or throat; difficulty breathing; or severe hives. As Klavocin is a penicillin-class antibiotic, it should not be taken by patients with a known penicillin allergy.
  • Liver Problems: Yellowing of the skin or eyes (jaundice), severe nausea, vomiting, or dark urine can indicate liver dysfunction. These reactions, including cholestatic jaundice, may occur during or shortly after treatment.
  • Severe Diarrhea: Persistent or severe watery diarrhea, especially if it contains blood or mucus, can be a sign of Clostridioides difficile-associated diarrhea (CDAD), which may occur even weeks after stopping the medication.
  • Severe Skin Reactions: Rarely, life-threatening skin conditions like Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), or Acute Generalized Exanthematous Pustulosis (AGEP) may develop, characterized by fever, flu-like symptoms, and blistering or peeling of the skin.

Important Safety Notes

  • Drug Interactions: Klavocin may reduce the effectiveness of oral contraceptives (birth control pills). Consult a healthcare professional about using alternative or supplementary contraception.
  • Pre-existing Conditions: Patients with a history of liver disease, severe kidney impairment, or mononucleosis should discuss these conditions with their doctor before starting Klavocin.

Overdose and Emergency Response

Overdose and When to Seek Help

Klavocin is a brand name for the combination medication Amoxicillin and Clavulanate Potassium. Information regarding overdose is based on regulatory documentation for this combined formulation.

Documented Overdose Profile

Overdose of Amoxicillin and Clavulanate is primarily associated with gastrointestinal symptoms, with vomiting being the most likely immediate effect. In the event of ingestion of large overdoses, the combination drug is documented to pose a risk of damage to two critical physiological systems:

  • Nervous System
  • Liver (Hepatic dysfunction and cholestatic jaundice have been reported in the general use context and warrant close monitoring in all patients with hepatic impairment).

Required Emergency Action

If an overdose is witnessed or suspected, you must immediately contact a healthcare professional or a poison control center for further advice. This procedural step is explicitly required for any overdose situation, regardless of the severity of initial symptoms.

General first aid instructions state: DO NOT induce vomiting if the product is swallowed. Seek urgent medical attention if symptoms occur or if the individual has collapsed, is experiencing a seizure, or is unable to be awakened, at which point emergency services should be called immediately.

Therapeutic Uses of Klavocin

What Klavocin Treats: Main Uses and Benefits

Klavocin (Amoxicillin/Clavulanate) is relevant in clinical contexts where bacterial resistance is a primary concern, and is applied to assist in managing infections. The combination is commonly used to help address a broad range of bacterial infections where resistance may be a factor, including those affecting the lower respiratory tract, middle ear, sinuses, skin and soft tissues, and the urinary tract. This contributes to managing symptoms that interfere with daily functioning. The combination is relevant for easing symptoms linked to infections of the ear, lungs, sinus, skin, and urinary tract.


Therapeutic Symptom Relief

This medication is commonly used across conditions presenting with acute episodes, such as pneumonia, rhinosinusitis, and cellulitis. These are conditions presenting with systemic or localized discomfort, often marked by fever, earache, facial pressure, or swelling. The primary therapeutic benefit is to apply supportive symptom management which helps ease the overall symptom burden associated with the infection.

“The primary goal of this combination is to provide supportive relief during difficult episodes by helping to manage symptoms that interfere with daily comfort.”

The key clinical benefit is its relevance for managing infections where bacterial resistance is a factor. It supports managing infections that present with heightened symptoms, such as those associated with osteomyelitis or bite wounds. It helps ease the impact of symptoms on routine activities and assists with maintaining functional stability during recovery.

Quick Fact Description
Relief for Pain Helps manage localized pain and discomfort stemming from conditions like acute otitis media and dental abscesses.
Relief for Systemic Discomfort Contributes to easing general symptoms related to systemic imbalance, such as fever and malaise.
Relief for Functional Strain Supports relief from symptoms that create noticeable strain on function, like difficulty breathing in acute respiratory infections.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Klavocin

The eligibility for Klavocin (Amoxicillin/Clavulanate) is strictly defined by regulatory documents, distinguishing between those permitted to use the medicine and those for whom use is contraindicated or restricted.

Absolute Contraindications (Must Not Use):

Klavocin is contraindicated in patients with a history of serious hypersensitivity reactions to any penicillin or to other beta-lactam agents, such as cephalosporins. It is also prohibited for individuals with a prior history of cholestatic jaundice or hepatic dysfunction associated with previous Amoxicillin/Clavulanate use.

Condition-Based Restrictions:

  • Severe Renal Impairment: Use of certain high-dose formulations (e.g., 875 mg/125 mg) is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min). Other formulations require mandatory dose adjustment.
  • Infectious Mononucleosis: Use is not recommended due to the high risk of developing a non-allergic rash.
  • Hepatic Impairment: Patients with liver dysfunction may use the medicine but require caution and active monitoring.

Age and Physiological Status:

  • Pediatric Use: Dosing is weight-based. Specific tablet ratios are not established for children weighing less than 40 kg.
  • Pregnancy and Lactation: Use during pregnancy is generally advised only when clearly needed (FDA Category B). Both active ingredients are excreted into human milk, requiring caution.

What should I know about interactions with other medicines?

The official regulatory profile for Klavocin (Amoxicillin/Clavulanate) strictly defines interaction patterns based on changes to drug exposure and concurrent physiological effects documented in government labeling.

Documented Interaction Restrictions

Interacting Product Official Interaction Outcome or Restriction
Methotrexate Co-administration is formally prohibited due to the risk of increased Methotrexate toxicity, stemming from reduced renal clearance by the amoxicillin component.
Probenecid Co-administration is not recommended as it increases and prolongs amoxicillin plasma concentrations by inhibiting renal tubular secretion.
Oral Anticoagulants Concurrent use is documented to be associated with abnormal prolongation of prothrombin time (increased INR).
Oral Contraceptives The official label states that Klavocin may reduce the efficacy of combined oral contraceptives.
Allopurinol Co-administration is documented to increase the incidence of skin rashes.
Food/Meals Administration is required at the start of a meal to enhance the absorption of the clavulanate component.
Laboratory Tests High urinary concentrations of amoxicillin may result in false-positive reactions when testing for glucose in urine using non-enzymatic methods.

These mandated interaction parameters establish restrictions on co-administration based on official pharmacokinetic and pharmacodynamic outcomes. This documentation is the sole basis for defining the product's required administration constraints and restrictions.

Mechanism of Action

The action of Klavocin, a combination of Amoxicillin and Clavulanic acid, is purely bactericidal, achieved through a strategic two-part mechanism targeting the structural integrity and defense mechanisms of susceptible bacteria.


Disabling the Bacterial Cell Wall Building Machinery

The primary mechanism relies on Amoxicillin irreversibly inhibiting key bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are responsible for cross-linking the peptidoglycan chains that form the rigid bacterial cell wall. By binding covalently to these transpeptidases, the antibiotic halts the final construction of the cell wall. This action compromises the cell’s structural integrity, leading to cell lysis (rupture) due to internal osmotic pressure.


Overcoming Bacterial Defense Through Enzyme Protection

The role of Clavulanic acid is protective: it functions as a mechanism-based inhibitor of beta-lactamase enzymes. These bacterial defense enzymes would otherwise destroy Amoxicillin by hydrolyzing its beta-lactam ring. Clavulanic acid binds permanently to the active site of the beta-lactamase enzyme, neutralizing it. The synergistic effect ensures that the Amoxicillin remains intact and available to execute its cell-wall-disrupting mechanism in the presence of beta-lactamase enzymes.

Dosage and Administration Information

Klavocin (Amoxicillin/Clavulanate) is administered through either the oral route, using film-coated tablets, chewable tablets, or a prepared oral suspension, or the intravenous (IV) route for more severe infections or when starting therapy. The official administration guidelines mandate that oral formulations be taken at the start of a meal to enhance the absorption of the clavulanic acid component and mitigate potential gastrointestinal effects.

Dosing is determined based on the amoxicillin content and the type or severity of the infection. Standard adult dosing patterns often utilize 875 mg every 12 hours or 500 mg every 8 hours. For pediatric patients weighing less than 40 kg, dosing is weight-based, determined in milligrams per kilogram per day (mg/kg/day) and divided into two or three daily administrations. A critical instruction related to use is the non-substitutability of different tablet strengths and ratios, as the proportion of the clavulanic acid component must remain consistent per dose.

The use of Klavocin is structured as a time-bound course of treatment. The standard duration typically ranges from 5 to 14 days, and treatment should not be extended beyond 14 days without a thorough medical review. Dose adjustments are required for patients with altered renal function; specifically, individuals with a creatinine clearance of le 30 mL/min must have their dosing interval extended or the dose reduced to align with altered drug clearance patterns.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Research and Preclinical Activity

Research explored the preclinical activity of [DRUG NAME]. Early laboratory research and Phase I clinical studies evaluated the pharmacokinetics and pharmacodynamics. These initial studies informed subsequent dosage levels for continued investigation.

Key Evidence Assessment

Research has assessed endpoints in individuals diagnosed with condition X. Studies examined outcomes related to pain and inflammation, which are areas of focus for patients.

Symptom Management (Short-Term Trials)

Multiple randomized, controlled trials (RCTs) involving [NUMBER] participants investigated short-term periods, typically over 4 to 12 weeks. Key findings from these studies included:

  • Pain Score: Trials evaluated differences in self-reported pain scores compared to a placebo group.
  • Inflammation Markers: Studies examined circulating biomarkers associated with inflammation (e.g., [MARKER A] and [MARKER B]).
  • Timing of Change: Research examined the timing of reported symptomatic changes in the first week of treatment.

Prevention of Recurrence (Long-Term Trials)

Longer-term research, including follow-up studies spanning up to [NUMBER] years, investigated findings related to the duration of symptom recurrence.

  • Recurrence Rate: The primary outcome measured was the percentage of participants who experienced a recurrence of condition X symptoms compared to a control group or baseline data.
  • Quality of Life: Trials evaluated differences in standardized quality of life (QoL) metrics over the extended study period.

Drug Interactions and Absorption

Studies have assessed the use of the drug in individuals with moderate condition X. Research has also explored factors influencing drug absorption and potential interactions.

Administration and Bioavailability

Research has explored administration relative to a meal, finding that consuming [DRUG NAME] alongside food was associated with a higher peak concentration (Cmax) compared to administration in a fasted state. The rate of absorption was reported as slower in these studies.

Combination Treatments

Research evaluated whether combining [DRUG NAME] with a secondary treatment (e.g., [SECONDARY DRUG]) affected study adherence and the reporting of adverse events.

Key Studies & References Clinical Guideline for the Management of Recurrent Inflammatory Disorders, Section 3: Targeted Therapies

Frequently Asked Questions (FAQ)

Common questions about Klavocin (FAQ)


Q: Why is Klavocin sometimes prescribed for skin infections?

Regulatory documents state that Klavocin is officially indicated for the treatment of Skin and Skin Structure Infections caused by susceptible bacteria. Its ability to combat certain bacteria that are resistant to standard penicillin antibiotics is consistent with its authorized use in these conditions.

Q: How long does Klavocin stay in your system after the last dose?

The active components of Klavocin are typically cleared from the body relatively quickly. However, according to official product information, severe side effects, such as serious diarrhea caused by C. difficile, have been reported to occur months after the final dose. This demonstrates that adverse effects may sometimes occur well after the treatment is completed.

Q: Is there a difference between Klavocin and taking amoxicillin alone?

Yes, there is a fundamental difference. Klavocin is a combination drug designed to provide broader coverage than amoxicillin alone. The clavulanic acid component serves to block the bacterial defense enzymes (beta-lactamases) that would otherwise destroy the amoxicillin, thereby retaining the primary antibiotic's intended action.

Q: What safety information is available for Klavocin use during pregnancy?

Klavocin is classified as Pregnancy Category B by the FDA. This classification means that animal reproduction studies have not shown evidence of harm to the fetus. However, official information advises that the medication should only be used during pregnancy when a healthcare professional determines it is clearly needed.

Q: Does Klavocin interact with common over-the-counter pain relievers?

Specific interactions with common over-the-counter (OTC) pain relievers are not listed in the mandated drug interaction tables. However, official labeling advises patients to inform their healthcare provider about all prescription and nonprescription medicines and supplements they are taking as a general safety precaution.

Q: Are there any specific food restrictions while taking Klavocin?

The official documents only provide the instruction to take Klavocin at the start of a meal to enhance drug absorption and reduce gastrointestinal upset. No other specific food items or beverages, such as dairy or citrus, are restricted in the mandated warnings.

Q: Can Klavocin be used for a dental infection?

Official information indicates that Klavocin is effective against the types of bacteria commonly responsible for infections. For this reason, it is often a choice for treating odontogenic infections, which are those originating in the tooth or surrounding tissues.

Q: What happens if I accidentally miss a dose of Klavocin?

Regulatory documents provide clear guidance for this situation. The official instruction is that if a dose is missed, one may take it as soon as possible. However, if the timing is close to the next scheduled dose, the instruction is to skip the missed dose and continue with the regular schedule. Official warnings state that a double dose should not be taken.

Q: Can Klavocin make me feel tired, weak, or dizzy?

While tiredness, weakness, and dizziness are generally not listed among the most common effects, official product documents sometimes mention these symptoms. They are noted as being associated with rare or serious side effects, such as hepatic dysfunction or severe allergic reactions. Headache is listed separately as a common mild side effect.

Q: Is there a maximum age limit listed for using Klavocin according to official sources?

No maximum age limit is specified in regulatory documents. For elderly patients, official product information states that the dose is typically the same as for adults, unless there is evidence of impaired kidney function. Dosing adjustments are primarily noted for kidney function, not age alone.

Q: Are there any known interactions between Klavocin and common herbal remedies?

Specific interaction data with individual herbal remedies is typically not listed in the mandated regulatory tables. However, official labeling strongly advises patients to inform their healthcare provider about all prescription, nonprescription medicines, vitamins, nutritional supplements, and herbal products they are taking.

Q: Does Klavocin come in different strengths, like 250mg or 500mg?

Yes, Klavocin is available in multiple dosage forms and strengths, reflecting different patient needs. Official information confirms the existence of tablets that contain 500 mg or 875 mg of amoxicillin and several different concentrations of the oral suspension.

Q: What are the signs that Klavocin is not working to clear the infection?

The official label lists severe symptoms that require immediate medical attention, which may signal a worsening infection or a serious drug reaction. These symptoms include fever, confusion, weakness, or little to no urination. Official warnings indicate that worsening symptoms are a reason for immediate consultation.

Q: Can Klavocin cause headaches or migraines?

Headache is reported in clinical trials as an other mild side effect associated with the medication. This finding is included in the full list of potential adverse reactions documented by regulatory bodies.

Q: What if I feel better before my Klavocin prescription is finished?

Official warnings state that skipping doses or not completing the full prescribed course of therapy may decrease the effectiveness of the treatment. Furthermore, official information indicates that incomplete courses carry a risk for the development of antibiotic resistance.

Q: Are there official warnings about combining Klavocin with alcohol?

Official documentation does not list a direct interaction between Klavocin and alcohol. However, official safety information indicates that consuming alcohol may increase the risk of experiencing certain side effects like nausea, vomiting, and potential liver problems.

Q: Does taking Klavocin affect probiotic supplements?

Specific interaction data with probiotic supplements is not typically listed in mandated regulatory tables. Official labeling advises patients to inform their healthcare provider about all prescription, nonprescription medicines, vitamins, and nutritional supplements they are taking.

Q: Can Klavocin tablets be split or crushed to make them easier to swallow?

Official documentation stresses the non-substitutability of different tablet strengths and ratios. As altering the tablet form may impact drug absorption, the tablets are generally designated to be swallowed intact, according to the official administration instructions.

Q: Are the common side effects of Klavocin usually mild and temporary?

Common side effects like diarrhea, nausea, and skin rash, are frequently reported in clinical data and are generally considered mild. However, official safety notes indicate that the occurrence of any persistent or severe symptoms is a reason for seeking medical advice.

Q: What kind of specific bacteria is Klavocin designed to kill?

Klavocin is designed to treat infections caused by susceptible organisms. Specifically, its combination formula allows it to effectively kill bacteria that produce beta-lactamase enzymes, which are bacteria that are resistant to standard amoxicillin alone.

Q: Is Klavocin considered safe for use in children?

Yes, Klavocin has established use in children as young as 3 months old according to regulatory information. Use in pediatric patients requires careful weight-based calculation by a prescriber. Official information notes that certain high-strength tablet formulations are not recommended for children weighing less than 40 kg.

How should Klavocin be stored and disposed of?

How to Store and Dispose of Klavocin (Amoxicillin/Clavulanate Potassium)

Storage requirements for Klavocin vary based on the medication form, and all forms must be kept out of the reach of children.


Storage Conditions

Formulation Required Storage Condition Stability/Handling Rule
Tablets / Dry Powder Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) in the original, tightly closed container Must be protected from moisture
Reconstituted Suspension Store in a refrigerator (2 C to 8 C / 36 F to 46 F) Do not freeze; Discard after 10 days

Disposal

Disposal of unused, expired, or remaining medicine, including the liquid suspension, is required to follow local regulatory requirements for pharmaceutical waste. The medication should not be discarded down a sink or toilet unless explicitly instructed by a take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Klavocin found in:

A-Z Index: